What is Nuvectis Pharma, Inc.'s (NVCT) StockRank?

MoatMap's StockRank for Nuvectis Pharma, Inc. (NVCT) is 22/100, with a Sell signal. This is a composite score combining Quality (21), Value (22), and Momentum (69) factor ranks across MoatMap's 19,000+ stock universe.

Does Nuvectis Pharma, Inc. have an economic moat?

Nuvectis Pharma, Inc. (NVCT) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Nuvectis Pharma, Inc. a buy, hold, or sell?

MoatMap's current signal for Nuvectis Pharma, Inc. (NVCT) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Nuvectis Pharma, Inc. in?

Nuvectis Pharma, Inc. (NVCT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

NVCT

SELLREMOVE

Nuvectis Pharma, Inc. · Healthcare · United States · $270M · Avg Vol: $1M/d

StockRank

P/E (TTM)

—

ROE

-154.4%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Nuvectis Pharma is an early-stage oncology drug developer with a low quality score of 21. It lacks commercialized products, pricing power, or the validated manufacturing scale that would allow it to benefit from the CDMO pricing power cycle.

COMPANY DESCRIPTION

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for the treatment of cancer. The company focuses on advancing a pipeline of proprietary oncology drug candidates, aiming to address significant unmet needs in various tumor types through targeted approaches and novel mechanisms of action.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-1.51	-1.43	-1.11	-1.32	—
Shares	15M	17M	19M	26M	+75.4%
Debt	6M	7M	9M	13M	29.1%
Equity	14M	12M	10M	18M	9.0%
Op CF	-14M	-16M	-12M	-16M	—
Inv CF	0	0	0	0	—
Fin CF	28M	15M	12M	29M	—

PRICE (1M)+25.4%

SMA 50SMA 200

$11.15

RSI (14)

65.9

52W High

$13.34

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-149.8%3.2

ROE

-154.4%5.0

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-28.9%10.4

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

2.27x42.4

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

20.0x5.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

84%79.5

RS 6M

39%92.4

SMA 50/200

1.22x90.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+27%38.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$270M

P/E (Forward)

-11.2x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NVCT are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
NVCT	Nuvectis Pharma, Inc.(you)	$270M	22	SELL
OBIO	Orchestra BioMed Holdings, Inc.	$238M	22	SELL
RZLT	Rezolute, Inc.	$315M	21	SELL
ARCT	Arcturus Therapeutics Holdings Inc.	$225M	22	SELL
ARMP	Armata Pharmaceuticals, Inc.	$298M	26	SELL
RNAC	Cartesian Therapeutics, Inc.	$212M	23	SELL
RCKT	Rocket Pharmaceuticals, Inc.	$330M	21	SELL
CNTN	Canton Strategic Holdings, Inc.	$217M	24	SELL
LRMR	Larimar Therapeutics, Inc.	$363M	23	SELL
CNTX	Context Therapeutics Inc.	$260M	16	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Nuvectis Pharma, Inc. (NVCT) — Stock Score Summary

Nuvectis Pharma, Inc. (NVCT) has a MoatMap StockRank of 22/100 based on Quality (21/100), Value (22/100), and Momentum (69/100) factor scores. The current signal is SELL. Nuvectis Pharma is an early-stage oncology drug developer with a low quality score of 21. It lacks commercialized products, pricing power, or the validated manufacturing scale that would allow it to benefit from the CDMO pricing power cycle.

Key Financial Metrics

Price	$11.15
Market Cap	$270M
P/E (Forward)	-11.16
Price/Book	19.98
Return on Equity	-154.4%
Return on Invested Capital	-149.8%
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-9M

Nuvectis Pharma, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Nuvectis Pharma, Inc.’s (NVCT) StockRank?: MoatMap’s StockRank for Nuvectis Pharma, Inc. (NVCT) is 22/100, with a Sell signal. It is a composite of Quality (21), Value (22), and Momentum (69) factor ranks across MoatMap’s 19,000+ stock universe.
Does Nuvectis Pharma, Inc. have an economic moat?: Nuvectis Pharma, Inc. (NVCT) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Nuvectis Pharma, Inc. a buy, hold, or sell?: MoatMap’s current signal for Nuvectis Pharma, Inc. (NVCT) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Nuvectis Pharma, Inc. in?: Nuvectis Pharma, Inc. (NVCT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).